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Purpose: To describe the phenotype and genotype of three Mainland Chinese families affected by choroideremia (CHM).
Methods: Complete ophthalmic examinations were conducted in three unrelated Chinese families with CHM. Peripheral
blood samples were collected from the families for genetic and immunoblot analysis. All exons and flanking intronic
regions of the gene encoding Rab escort protein-1 (Rep-1) were amplified with PCR and screened for mutations with
Sanger sequencing. The three-dimensional structure of mutated Rep-1 was modeled using sequence homology with rat
proteins to analyze the effect of the mutation detected in one family.
Results: All affected males had characteristic signs and symptoms of CHM; however, central visual acuity impairment
occurred earlier than expected. All female carriers older than 45 years had pigmentary changes, and one female carrier
was symptomatic with vision loss. Three different mutations in Rep-1, c.1801–1G>A, c.1130 T>A, and c.612delAG, were
detected in the three families.
Conclusions: In Mainland Chinese families, the central visual acuity of male patients with CHM can be affected at an
early age (second decade), whereas female CHM carriers may manifest signs and symptoms at a later age (≥45 years).
One previously reported and two novel Rep-1 mutations were detected in three Chinese patients with CHM.
Choroideremia  (CHM)  is  an  X-linked  progressive
chorioretinal dystrophy [1]. Affected males experience night
blindness in their teenage years, followed by visual field loss
that  leads  to  legal  blindness  later  in  life.  Female  carriers
generally do not show serious visual impairment, but they may
have  patchy  areas  of  pigmentation  and  retinal  pigment
epithelium (RPE) degeneration due to random X-inactivation,
called lionization [2]. In most cases, CHM can be clinically
diagnosed  with  fundus  examination;  however,  because  of
interfamilial  and  intrafamilial  variability  in  the  clinical
manifestations of CHM, modern molecular genetic testing is
required to confirm the diagnosis [3].
The  CHM  gene  has  been  mapped  to  Xq21.2  [4].  It
consists of 15 exons spanning about 150 kb of genomic DNA
and  is  expressed  in  many  tissue  types,  including  retinal
photoreceptors, choroid, RPE, and lymphocytes [5]. CHM
mRNA  is  about  5.6  kb  long  and  encodes  an  intracellular
protein  of  653  amino  acids,  called  Rab  escort  protein-1
(Rep-1), which is involved in the prenylation of Rab GTPases
and intracellular vesicular trafficking [5].
At  present,  according  to  the  Human  Gene  Mutation
Database (HGMD), there are 113 reported mutations in the
Rep-1  gene,  including  missense/nonsense,  splicing,  small
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deletions, small insertions, small indels, gross deletions, and
gross  insertions.  Reports  of  Asian  CHM  families  with
mutations are rare: Yip et al. [6] reported five mutations in
five separate Chinese families; Fujiki et al. [7] reported 15
mutations in 18 Japanese families.
In  this  study,  we  describe  the  results  of  clinical  and
molecular analyses of three Mainland Chinese families with
CHM. Two novel mutations as well as a previously reported
mutation in Rep-1 were identified.
METHODS
This study was approved by the Institutional Review Board
of Peking Union Medical College Hospital and conformed to
the tenets of the Declaration of Helsinki and the Guidance of
Sample  Collection  of  Human  Genetic  Diseases  by  the
Ministry of Public Health of China. Informed consent was
obtained from all subjects before entry into this study.
Participants: Patients and their family members were
seen  in  the  Department  of  Ophthalmology,  Peking  Union
Medical College Hospital. Except ocular diseases, they were
generally  healthy.  Nothing  remarkable  was  found  in  the
medical history in all the participants. Complete ophthalmic
examination  was  supplemented  with  optical  coherence
tomography  (OCT;  Topcon,  Tokyo,  Japan),  visual  field
testing  (Octopus  101),  and  full  field  electroretinography
(ERG; RetiPort ERG system, Roland Consult, Wiesbaden,
Germany). The ERG was recorded using corneal “ERG jet”
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309contact lens electrodes under conditions that conformed to the
standards  of  the  International  Society  for  Clinical
Electrophysiology of Vision (ISCEV).
Mutation  screening  of  candidate  genes:  Peripheral
bloods were drawn and collected in EDTA tubes. Samples
were preserved in refrigerator before use. Genomic DNA was
isolated from the leukocytes using a QIAmp DNA Blood Midi
Kit  (Qiagen,  Hilden,  Germany)  according  to  the
manufacturer’s protocol and kept in freezer. Genomic DNA
was amplified from all exons and flanking intronic regions of
the Rep-1 gene with PCR [8]. Pairs of oligonucleotide primers
Figure  1.  Family  pedigrees  of  the  three  mainland  Chinese
choroideremia families. X-linked inheritance pattern is clear. Closed
symbols indicate individuals with choroideremia (CHM) and open
symbols indicate unaffected subjects. Dotted circles indicate female
carriers. Arrows indicate probands. Slash indicates deceased person.
specific for each exon were used to amplify the entire coding
region  of  the  Rep-1gene  [3].  PCR  products  were  directly
sequenced on an ABI Prism 3730 Genetic Analyzer in both
directions (Applied Biosystems, Foster City, CA).
RNA analysis: After mutations were initially identified at
the DNA level, a second fresh venous blood sample was
obtained from members of family 1. Total RNA was extracted
using a commercial kit (PAXgene Kit; Qiagen) according to
the manufacturer’s instructions. Reverse Transcriptase PCR
(RT–PCR) primers were chosen from exon 12 to exon 15. RT–
PCR products were directly sequenced on an ABI Prism 3730
Genetic Analyzer.
Immunoblot  analysis:  Proteins  were  extracted  from  a
lysate of leukocytes from members of family 1. Proteins were
separated with SDS–PAGE on 4%–20% gradient mini-gels
and  transferred  onto  a  0.45-µm  nitrocellulose  membrane
(Invitrogen, Grand Island, NY) and then probed with mouse
anti-human  anti-Rep-1  antibody,  clone  2F1  (Santa  Cruz
Biotechnology, City Santa Cruz, CA). Immunoreactivity was
detected with a corresponding secondary anti-IgG antibody
conjugated with horseradish peroxidase (Zymed Lab, Inc.,
San  Francisco,  CA)  and  imaged  on  X-ray  film  using
SuperSignal  West  Pico  or  SuperSignal  West  Dura
Chemiluminescent Substrates (Pierce, Rockford, IL).
Molecular modeling: Molecular modeling of the Rep-1
structure and splice mutations was performed as described
earlier [9]. Briefly, a model of human Rep-1 was built by
homology modeling based on 2.2 crystal coordinates for the
rat Rep-1 protein in a complex with monoprenylated Rab7
protein  (PDB  file:  1vg0)  as  the  structural  template  [10].
Primary  sequences  were  aligned  with  Needleman  and
Wunsch’s method [11], incorporated in the program Look,
version  3.5.2  [12,13]  for  three-dimensional  structure
prediction. Finally, full-length monomeric Rep-1 and changes
in  protein  structure  corresponding  to  the  detected  gene
mutations were built with the automatic segment matching
method in the Look program [14] followed by 500 cycles of
energy minimization. In the full-length Rep-1 structure, the
elements of the structure corresponding to the unresolved
fragments of Rep-1 were generated in a conformation that has
not  been  justified  experimentally,  to  show  the  possible
location and structural role of these fragments in Rep-1. The
same program generated the conformation of the protein with
the  detected  mutation  and  refined  this  structure  with  500
cycles of self-consistent ensemble optimization [13], which
applies  statistical  mechanical  mean-force  approximation
iteratively to achieve the global energy minimum structure.
The geometry of the predicted structures was tested using the
program Procheck [15].
RESULTS
Clinical findings: All pedigrees of the families showed X-
linked transmission (Figure 1). Patient F1-III-1 and patient
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311F3-III-2 were myopic. All affected male patients experienced
poor night vision at an early age and decreased visual acuity
in the third, fourth, and fifth decades. The patients’ clinical
findings are listed in Table 1. One female carrier, F3-II-2,
showed signs of decreased vision and had a reduced visual
field, reduced ERG amplitudes, and fundus changes in the
sixth decade. Carriers F1-II-2, F2-II-2, and F2-II-3 did not
have any symptoms, but fundus changes were observed and
documented with retinal photography (Table 2).
DNA analysis: A transition mutation (G to A) at nucleotide
position 1801–1 was detected in family 1, which is in the
splice acceptor site of intron 14. A c.1130 T>A (Leu377Ter)
mutation  was  detected  in  family  2,  and  a  c.612  del  AG
(p.Glu204Glufsx18)  mutation  was  detected  in  family  3.
Carriers in the three families were heterozygous for these
mutations.  A  synonymous  variation,  c.1125  T/C
(Phe375Phe), was also found in family 2 (Figure 2).
Real-time polymerase chain reaction analysis: Sequencing of
the RT–PCR product from family 1 revealed that G is missing
from cDNA position 354 of a family 1 patient. This is as a
result of the altered splice site at this location (Figure 3).
Western blot: Western blot analysis was performed on protein
samples from members of family 1, the patient, his mother,
and  unaffected  brother.  Blot  incubation  with  mouse  anti-
Rep-1, clone 2F1, demonstrated the absence of any Rep-1
protein band in the patient and showed a reduced amount of
the Rep-1 protein in the female carrier when compared to the
band intensity of the unaffected brother (Figure 4).
Molecular  modeling:  The  downstream  cryptic  splice  site
detected in family 1 causes changes in the last 63 amino acid
residues at the C-terminus of the protein. This change will
affect  the  conformation  of  Rep-1  at  the  C-terminus  by
decreasing the content of the regular α-helical structure as
shown in Figure 5. Based on molecular modeling, the changes
TABLE 2. CLINICAL FEATURES OF CARRIERS WITH CHM.
Patient Age of test Symptoms and signs
F1-II-2 45 hypopigment changes in the midperiphery area fine RPE mottling patchy areas of chorioretinal atrophy (Figure 7A)
F2-II-2 71 NA; Fundus: diffuse punctate hypopigmentary changes (Figure 7B)
F2-II-3 67 NA; Fundus: diffuse punctate hypopigmentary changes
F3-II-2 69 Decreased vision
Refraction:OD 0–3.50×130 20/60; OS +0.50+1.25×40 20/30;
Fundus: see Figure 7C
ERG: reduced rod and cone amplitude
VF: constricted, central 20° VF
F3-IV-1 17 Refraction; OD −1.25–0.75×160 20/20; −1.00–1.00×8 20/20
Figure 2. Electropherograms of the three
families. The sequencing results show
three different mutations. A: A c.1801–
1G>A splice mutation was detected in
family 1. B: A c.1130 T>A (Leu377Ter)
mutation and a synonymous variation:
c.1125 T>C were found in family 2. C:
A  c.612  del  AG  (p.Glu204GlufsX18)
mutation was detected in family 3. All
the carriers were heterozygous.
Molecular Vision 2012; 18:309-316 <http://www.molvis.org/molvis/v18/a34> © 2012 Molecular Vision
312caused by the splice mutation might destabilize the structure
of the helix (orange H) that potentially could affect the global
stability of the Rep-1 protein (Figure 5).
DISCUSSION
This  report  is  the  first  to  describe  genotype/phenotype
findings  in  Mainland  Chinese  families  affected  with
choroideremia. Clinical findings of the male patients included
early-onset night blindness, constricted visual fields, reduced
ERG  rod  and  cone  response  amplitudes,  as  well  as
chorioretinal atrophy consistent with the diagnosis of CHM
(Figure 6). For the males affected with CHM in our study,
central  vision  loss  occurred  in  the  third,  fourth,  and  fifth
decades, which is much younger than reported central vision
loss occurring between the sixth and eighth decades [16].
Roberts et al.’s study of 115 CHM males (mean age: 39 years)
showed that 84% of males under the age of 60 years had visual
acuities of 20/40 or better and 35% of those over 60 years of
age had visual acuities of 20/200 or worse, suggesting a slow
rate of visual acuity loss and a generally good prognosis for
retaining central visual acuity until the seventh decade [17].
An  Internet-based  survey  of  patients  with  CHM  with
responses mainly from North America, presumably of largely
Caucasian origin (unpublished data from Qi Zhou and Ian
MacDonald),  found  that  60%  of  respondents  had  non-
functional vision (defined as vision less than 20/400 OU and
field less than 5 degrees) and were between 50 and 70 years
of age. This result raised questions regarding whether our
Figure  3.  Reverse-transcriptase  (RT)-PCR  analysis.  Sequencing
results from the proband of family 1 show a deletion of G on the
mutated  exon  14  (upper  sequence).  Arrow  indicates  the  border
between exon 14 and exon 15.
observations are related to ethnicity or other modifiers affect
the  rate  of  vision  loss.  Our  study  does  not  answer  these
questions definitively; further studies on the CHM phenotype
in Chinese families are needed. We should, however, consider
the  possibility  that  Chinese  patients  with  CHM  may
experience severe vision loss at an earlier age than those of
Caucasian origin.
In our study, the female carriers in families 1 and 2 were
asymptomatic but had pigmentary changes in the fundus. One
older female carrier (age 69) in family 3 showed signs and
symptoms similar to affected male patients (Figure 7). This
Figure 4. Western blot results from the family 1 show the absence of
Rep-1 protein in the patient (line 2) and a reduced amount of Rep-1
in the female carrier (Line 1). Lane 3 is the  normal brother of  the
patient. A: Mouse anti-REP-1, clone 2F1 demonstrated the absence
of Rep-1 protein in the patient and a reduced amount of Rep-1 protein
in the female carrier. B: β-actin antibody was used as a loading
control to ensure an adequate protein sample in each lane.
Figure 5. The effect of the downstream cryptic splice site on a three-
dimensional structure of the Rep-1 protein is shown. The mutation
cause changes in the last 63 amino acid residues at the C-terminus.
The superposition of ribbon structures for wild-type and mutant
proteins are shown in light gray and magenta, respectively. In the
wild-type protein, the α-helix that might be critical for maintaining
global protein stability is included in the orange box and labeled with
H.
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313may  be  due  to  skewed  X-chromosome  inactivation.  Even
though female carriers are generally asymptomatic, careful
Figure 6. Fundus photographs and fluorescein fundus angiography
from  choroideremia  (CHM)  patients.  Characteristic  retinal  and
choroidal atrophy and relatively preserved macular area are revealed.
(A) F1-III-1, (B) F2-III-2, and (C) F3-III-2.
fundus  examination  can  reveal  signs  of  chorioretinal
degeneration  after  the  second  decade  [16].  Results  (to  be
published) from the Internet-based survey (Qi Zhou and Ian
MacDonald)  indicate  that  age  is  a  significant  factor  in
predicting symptoms and signs in female CHM carriers. In
family 3, the 69-year-old carrier showed significant CHM
signs and symptoms, while the younger carrier (age 17) did
not  show  any  signs  and  symptoms.  The  difference  in
phenotype between the two carriers is likely related to age and
the progressive nature of signs in female carriers. Compared
to  Caucasian  patients,  Chinese  patients  have  significantly
more  pigment  in  the  RPE  and  choroid,  making  detecting
fundus  changes  in  asymptomatic  Chinese  patients  more
difficult; therefore, asymptomatic but mildly affected females
are likely under-reported. Since signs and symptoms manifest
with time, careful examination and close follow-up should be
conducted in CHM carriers.
Sequence analysis of the 15 exons and adjacent splice
sites of the Rep-1 gene allows for detecting mutations in
approximately 60%–95% of affected males [16]. Using this
strategy,  three  different  mutations  were  detected  in  three
Chinese families; carriers in each family were heterozygous
for these mutations. A previously reported G to A transition
mutation (c.1801–1) was found in the Rep-1 gene of family 1;
and RT–PCR revealed a G deletion in the resulting cDNA.
This  transition  at  c.1801–1  alters  the  invariant  AG
dinucleotide of the acceptor splice site in intron 14 leading to
changes in the protein sequence involving the 63 carboxy
terminal amino acid residues. In silico analysis showed that,
as  a  consequence,  the  mutant  protein  lacks  the  entire  C-
terminal  helix  of  the  wild-type  protein.  The  C-terminal
fragment  has  a  crucial  role  in  Rep-1  function  [19].
Recombinant rat Rep-1 protein lacking the 70 C-terminal
amino  acids  does  not  have  the  ability  to  assist  in  the
prenylation of Rab proteins [9,18]. The Rep-1 C-terminus
functions as a mobile lid that covers a conserved hydrophobic
patch on the surface of Rep-1 that binds the C-terminus of Rab
[19]. The lack of a Rep-1 band in the immunoblot analysis of
protein from the patient with CHM and the reduced Rep-1
band intensity in the carrier lane could result from the absence
of the protein or changes in its affinity for the monoclonal anti-
Rep-1 antibody. We predict this mutation in the splice site
may cause Rep-1 to be unstable and easily digested by the
cell’s proteolytic system or may give an effective complete
loss of protein through the nonsense mediated mRNA decay.
Two novel mutations, c.1130 T>A (p.Leu377Ter) and c.
612 del AG (p.Glu204Glufsx18), were detected in family 2
and family 3, respectively. The substitution c.1130 T>A is a
nonsense  mutation  expected  to  truncate  the  protein.  The
deletion c.612 del AG is predicted to produce a frameshift and
a premature termination codon, 18 codons downstream from
the mutation. Both mutations result in truncation of the Rep-1
protein. A truncation at p.Leu377 would significantly disrupt
Molecular Vision 2012; 18:309-316 <http://www.molvis.org/molvis/v18/a34> © 2012 Molecular Vision
314the structure of Rep-1 Domain I that contacts Rab proteins,
Figure 7. Fundus photographs of female carriers. A: (F1-II-2) Fine
pigment mottling in the midperiphary retina. B: (F2-II-2) Pigmentary
clumping changes are found in the posterior pole and peripheral
retina. C: (F3-II-2) A ring of retinal and choroidal atrophy is found
around the optic disc.
thereby rendering Rep-1 not only dysfunctional but also likely
structurally  unstable.  The  truncation  at  p.Glu204  would
further result in the loss of prenyl binding capabilities and
RabGGTase  function  due  to  the  complete  lack  of  Rep-1
Domain I in addition to Domain II disruption. Immunoblot
analysis  of  the  protein  from  these  two  families  was  not
performed  because  of  the  nature  of  the  mutations.  A
polymorphism, c.1125 T/C (p.Phe375Phe), was also found in
family 2; however, it does not lead to any amino acid change
and is therefore pathologically irrelevant.
Few  important  genotype-phenotype  correlations  have
been demonstrated in patients with CHM. Individuals with
full deletions of the Rep-1 gene seem to be no more adversely
affected than those with point mutations that will result in a
truncated, unstable protein [16]. In the families reported here,
all  affected  males  had  a  similar  range  and  severity  of
symptoms and experienced early central visual acuity loss.
One female carrier in family 3, with a mutation c.612 del AG
(p.Glu204Glufsx18) resulting in a shorter Rep-1 protein than
in families 1 and 2, had more severe CHM symptoms and
signs. Does a mutation resulting in a short peptide containing
only the N-terminal 204 amino acids of Rep-1 lead to an early-
onset disorder with more severe symptoms in female carriers?
Further examples may answer this question. As age seems
critical to the onset of signs and symptoms of CHM, the
younger carrier in family 3 should be followed up closely. Due
to the nature of her Rep-1mutation, she may develop early and
severe symptoms and signs resembling those of her older
relative.
The findings from our study of three Mainland Chinese
CHM families add to the spectrum mutations in the Rep-1
gene and will certainly aid in future mutation screening and
genetic counseling in Chinese patients.
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